Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Love's Labor Lost and Maternal Mortality, 30 Years Later.

Birth (Berkeley, Calif.)·2026
Same author

Risk Prediction of 2-Year Incident Cognitive Impairment in Maintenance Hemodialysis Patients: A Multicenter Prospective Cohort Study.

Kidney360·2026
Same author

Artificial Intelligence in Hemodialysis: Current Clinical Applications and Future Perspectives.

Hemodialysis international. International Symposium on Home Hemodialysis·2026
Same author

Exploring the Relationship between Dietary Intake and Clinical Outcomes in Peritoneal Dialysis Patients Stratified by Serum Albumin Levels: A 12-Year Follow-Up Using Fine-Grained Electronic Medical Records Data.

Health data science·2026
Same author

The impact of stigma on medication adherence among patients with multimorbidity: mediation analysis of medication literacy.

Frontiers in public health·2026
Same author

Dietary Knowledge, Health Belief, and Practice Among Hemodialysis Patients: A Structural Equation Modeling Study.

Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation·2026

相关实验视频

Updated: Jul 14, 2026

A Simple and Efficient Method for In Vivo Cardiac-specific Gene Manipulation by Intramyocardial Injection in Mice
06:42

A Simple and Efficient Method for In Vivo Cardiac-specific Gene Manipulation by Intramyocardial Injection in Mice

Published on: April 16, 2018

通过特定的 Janus 激酶3 抑制剂预防器官异位移植排斥.

Paul S Changelian1, Mark E Flanagan, Douglas J Ball

  • 1Immunology Group, Department of Antibacterials and Immunology, Pfizer Global Researchand Development, Groton, CT 06340, USA. paul_s_changelian@groton.pfizer.com

Science (New York, N.Y.)
|November 1, 2003
PubMed
概括

通过CP-690,550抑制简氏激酶3 (JAK3) 显示出免疫抑制的前景. 这种JAK3抑制剂在临床前模型中延长了移植存活率,没有副作用,这表明人类器官移植的潜力.

更多相关视频

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
08:00

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity

Published on: July 10, 2019

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
08:15

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Published on: May 10, 2024

相关实验视频

Last Updated: Jul 14, 2026

A Simple and Efficient Method for In Vivo Cardiac-specific Gene Manipulation by Intramyocardial Injection in Mice
06:42

A Simple and Efficient Method for In Vivo Cardiac-specific Gene Manipulation by Intramyocardial Injection in Mice

Published on: April 16, 2018

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity
08:00

Enhancing the Engraftment of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes via a Transient Inhibition of Rho Kinase Activity

Published on: July 10, 2019

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
08:15

Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway

Published on: May 10, 2024

科学领域:

  • 免疫学 免疫学 免疫学
  • 药理学 药理学是指药理学的学科.
  • 移植科学 移植科学

背景情况:

  • 简氏激酶3 (JAK3) 对于细胞因子信号传递至关重要,使其成为免疫抑制的关键目标.
  • 在移植相关的免疫反应中,JAK3起着至关重要的作用.

研究的目的:

  • 开发和评估一种特定的,口服活性的JAK3抑制剂,名为CP-690,550.550.
  • 在临床前移植模型中评估CP-690,550的疗效和安全性.

主要方法:

  • 开发一种选择性的JAK3抑制剂,CP-690,550.
  • 在小鼠心脏移植模型中评估CP-690,550.
  • 在Cynomolgus的脏移植模型中评估CP-690,550.

主要成果:

  • 在小鼠心脏和灵长类动物移植模型中,CP-690,550显著延长了存活时间.
  • 用CP-690,550治疗没有导致高血压,高脂血症或淋巴增殖性疾病.
  • 这种药物在临床前研究中表现出了有利的安全性.

结论:

  • 使用CP-690,550阻断JAK3,为器官移植中免疫抑制提供了一个潜在的治疗策略.
  • CP-690,550显示出需要免疫抑制的更广泛的临床应用的潜力.